Fig 2: Exogenous S100A6 promotes the proliferation of HepG2 cells. (a) Detection of the proliferation of HepG2 cells by MTT assay; *P < 0.05 and **P < 0.01. (b and c) Colony formation assay of the HepG2 cells treated with GST or GST-S100A6; *P < 0.05 and **P < 0.01. (d) Immunoblotting shows the CCND1 protein levels in HepG2 cells treated with GST or GST-S100A6.

Fig 3: Exogenous S100A6 promotes the ubiquitination of P53. (a) S100A6 promotes the degradation of P53 through proteasome; HepG2 cells were treated with GST/GST-S100A6 and BTZ (bortezomib); the protein levels of p53 normalized to GAPDH; *P < 0.05 and **P < 0.01. (b) S100A6 promotes the ubiquitination of P53; HepG2 cells were treated with GST/GST-S100A6 and BTZ (bortezomib), immunoprecipitated with anti-P53 antibody, and subjected to immunoblotting analysis using the indicated antibodies.

Fig 4: Exogenous S100A6 promotes the migration of HepG2 cells. (a and b) Detection of the migration of HepG2 cells by transwell assay; *P < 0.05 and **P < 0.01. (c) Immunoblotting shows the E-cadherin and vimentin protein levels in HepG2 cells treated with GST or GST-S100A6.

Fig 5: Identification of human GST-S100A6 by Coomassie blue staining and immunoblotting analysis. (a) Detection of recombinant proteins human GST-S100A6 and GST by Coomassie blue staining: GST-S100A6 is approximately 37 kDa and GST is approximately 26 kDa. (b) Detection of recombinant proteins human GST-S100A6 and GST by immunoblotting analysis.